A scaleable synthesis of fiduxosin

被引:53
作者
Haight, AR [1 ]
Bailey, AE [1 ]
Baker, WS [1 ]
Cain, MH [1 ]
Copp, RR [1 ]
DeMattei, JA [1 ]
Ford, KL [1 ]
Henry, RF [1 ]
Hsu, MC [1 ]
Keyes, RF [1 ]
King, SA [1 ]
McLaughlin, MA [1 ]
Melcher, LM [1 ]
Nadler, WR [1 ]
Oliver, PA [1 ]
Parekh, SI [1 ]
Patel, HH [1 ]
Seif, LS [1 ]
Staeger, MA [1 ]
Wayne, GS [1 ]
Wittenberger, SJ [1 ]
Zhang, WJ [1 ]
机构
[1] Abbott Labs, GPRD Proc Res & Dev, N Chicago, IL 60064 USA
关键词
D O I
10.1021/op049889k
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Fiduxosin (1) has been under development at Abbott Laboratories for the treatment of benign prostatic hyperplasia. A convergent strategy required methodologies for preparation of an enantiomerically pure 3,4-cis-disubstituted pyrrolidine and a 2,3,5-trisubstituted thienopyrazine in a regiospecific manner. A [3+2] cycloaddition of an enantiopure azomethine ylide followed by a diastereoselective crystallization was employed to prepare the benzopyranopyrrolidine in high diastereomeric and enantiomeric purity. Conditions for reduction of an O-aryl lactone susceptible to epimerization were developed, and cyclization of the alcohol/phenol to the ether was accomplished in high yield. The thienopyrazine was prepared by condensation of methyl thioglycolate and a regiospecifically prepared 2-bromo-3-cyano-5-phenylpyrazine. Conditions for effective halogen substitutive deamination to prepare regiospecific trisubstituted pyrazines will be described.
引用
收藏
页码:897 / 902
页数:6
相关论文
共 31 条